Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Pfizer
This study was closed to enrollment on 18 April 2011 due to inability to recruit patients on a timely basis as well as business reasons. Study closure was not related to any safety concerns.
Age
10–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Patients ≥18 years of age with advanced solid tumors for which the combination of figitumumab and pegvisomant are reasonable treatment options.
Patients between the ages of 10 and 18 years with advanced sarcomas for which there is no available curative therapy or therapy proven to prolong survival with an acceptable quality of life will be included in the Sarcoma Expansion Cohort.
Adequate recovery from prior therapies.
Adequate organ function (i.e. bone marrow, kidney, liver)
Total IGF-1 ≥100 ng/ml (13 nmol/L).
You may not be if
Concurrent treatment with any anti-tumor agents.
Pregnant or breastfeeding females.
Significant past history or active cardiac disease
